Does the daily risk assessment of adverse outcomes after percutaneous coronary interventions facilitate the personalized medicine approach?

New-generation drug-eluting stents (DES) comprise of a heterogenous group of coronary devices characterized by thin struts, biocompatible durable or biodegradable polymer coatings or polymer-free structure and limus-eluting drugs. Thanks to excellent early and long-term outcomes in patients undergoing percutaneous coronary interventions (PCI), new-generation DES are recommended in almost all patient and lesion subsets. Nevertheless, several...